CONGRESSOS

Els nostres metges oncòlegs i investigadors experts del laboratori són conferenciants, alhora que organitzadors de molts dels més importants seminaris i reunions científiques per tot el món.

Els resultats de les nostres investigacions sobre les causes del càncer i tractaments nous s'han presentat en els més importants congressos nacionals i internacionals.

SELECCIONA UN ANY PER VEURE EL
HISTÒRIC DE CONGRESSOS

Annual Congress, American Society of Clinical Oncology (ASCO)

DATA29/05/2015 - 02/06/2015

LLOC DE REALITZACIÓChicago, USA

Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699) Massuti B, Cobo M, Rodriguez-Paniagua J.M, Ballesteros A.I, Moran T, Arrabal R, Gonzalez Larriba J.L, Barneto I, Pun Y.W, De Castro J, Ponce Aix S, Baamonde C, Munoz M.A, Lopez-Vivanco G, Rivas J-J, Isla D, Lopez R, Sanchez J.M, Sanchez-Paya J, Rosell R. Abstract 7507. Oral.

[tornar]
EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients Karachaliou N, Nilsson J, Berenguer J, Gimenez Capitan A, Schellen P, Teixido C, Leonie Kuiper J, Drees E, Grabowska, van Keulen M, Tannous J, Heideman D, Thunnissen E, Dingemans A-M, Viteri Ramirez S, Tannous B, Drozdowskyj A, Smit E, Wurdinger T, Rosell R.
Abstract 8082. Poster
 
Association of non-disruptive P53 mutations with poor progression-free survival (PFS) in resected breast cancer treated with neoadjuvant chemotherapy Martinez-Bueno A, Baulies , Molina-Vila M.A, Bertran-Alamillo J, Gonzalez Cao M, Gonzalez X, Viteri Ramirez S, Karachaliou N, Teixido C, Sanchez-Ronco M, Tresserra F, Cusido M.T, Fabregas R, Rosell R. Abstract, 1042. Poster
 
IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome upfront Pignatti criteria and molecular profile in a retrospective analysis of a single-centre cohort from Spain Etxaniz O, Carrato C, de Aguirre I, Queralt C, Munoz A, Ramirez J.L, Rosell R, Villà S, Diaz, R Estival A, Teixido P, Indacochea A, Ahlal S, Vilà Martinez L, Balana C. Abstract 2046. Poster
 
ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability Scheffler M, Schultheis A, Teixido C, Yves S, Michels F, Morales-Espinosa D, Viteri S, Merkelbach-Bruse S, Fischer R, Fassunke J, Sebastian M, Heidi Serke M, Randerath W, Gerigk U, Ko Y-D, Krüger S, Schnell R, Rothe A, Rosell R, Büttner R, Wolf J. Abstract 8066. Poster
 
Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC) Camidge R, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Tsang Shaw A, Weiss G, Narasimhan N, Dorer N, Rivera V, Clackson T, Conlan M, Kerstein D, Haluska F, Gettinger. Abstract 8062. Poster

Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine
Bepler G, Chen W, Patrick S, Astrow S, Stephens C, Gandara D, Rosell R, Ramirez J.L, Scagliotti G, Busso S, Volante M, Novello S. Abstract 8036. Poster
 
Non-Small Cell Lung Cancer (NSCLC) harboring Epidermal Growth Factor Receptor mutations (EGFR-m) and breast cancer (BC): A retrospective analysis of a single institution. Moran T, Quiroga V, Carcereny Costa E, Cirauqui B, Margeli M, Vilà L, de los Llanos GIL Gil Moreno M, Indacochea A, Cuadra Urteaga J.L, Queralt C, de Aguirre I, Ramirez J.L, Castella E, Lopez Y, Mate J.L, Rosell R. Abstract e19112. Proceedings
 
RAP80 mRNA expression impact on sporadic high-grade serous ovarian cancer survival Romeo M, Karachaliou N, Chaib I, Queralt C, de Aguirre I, Carmen Gomez M, Sanchez-Ronco M, Radua J, Ramirez J.L, Rosell R. Abstract e16571. Proceedings
 
Prevalence of ROS1 translocation, HER2, and BRAF mutations in a cohort of advanced Non-Small Cell Lung Cancer (NSCLC) patients (p) triple negative (TN)
Carcereny Costa E, Estival A, Vilà Martinez L, de los Llanos Gil Moreno M, Moran T, Gutierrez B, Nancy Perez E, Luis Y, Jove J, Buges C, Quiroga V, Cuadra-Urteaga J.L, Cros S, Hardy-Werbin M, Teruel I, Ahlal S, Pardo N, Indacochea A, Capdevila L, Rosell R. Abstract e22139. Proceedings
 
BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p). Garcia Campelo R, Moran T, Cardenal F, Alonso-Jaudenes Curbera G, Carcereny Costa E, Pallares E, Camps C, Insa A, Lopez-Vivanco G, Porta R, Bastus R, Isla D, Reguart N, Bover I, Majem M, Massuti B, Ramirez J.L, Drozdowskyj A, Karachaliou N, Rosell R. Abstract e19078. Proceedings
 
Serial mutational analysis to monitor disease evolution in blood from advanced non small cell lung cancer (NSCLC) patients (p) Viteri Ramirez S, Mayo-de las Casas C, Jordana-Ariza N, Morales-Espinosa D, Molina-Vila M.A, Karachaliou N, Gonzalez Cao M, Simo-Perdigo M, Bertran-Alamillo J, Codony J, Garzon M, Perez-Rosado A, Martinez-Bueno A, Gonzalez X, Ovalle E, Rosell R. Abstract e19085. Proceedings
 
DNA repair- and apoptosis-pathways to regulate response to chemo-radiotherapy (CRT) in patients (p) with locally advanced head and neck cancer (HNC) Cirauqui B, Quiroga V, Chaib I, Sanchez B, Karachaliou N, Ramirez J.L, Quer A, Munoz A, Drozdowskyj A, Pollan C, Planas I, Verges J, Cuadras P, Massuet A, Lezcano C, Vilà Martinez L, de los Llanos Gil M, Hardy M, Rosell R, Margeli M.  
Abstract e17025. Proceedings

Analysis of gene expression in the re-replication pathway and selective blockade with checkpoint inhibitors as a potential therapeutic option in NSCLC Morales-Espinosa D, Molina-Vila M.A, Gimenez Capitan A, Garcia-Roman S, Bertran-Alamillo J, Mendez P, Ramirez-Serrano J.L, Codony C, Viteri Ramirez S, Karachaliou N, Rosell R. Abstract e13516. Proceedings
 
Association of high BIM mRNA levels with longer survival in advanced gastric cancer Wu N, Wei J, Yu L, Gimenez Capitan A, Sanchez J.J, Rosell R, Liu B.
Abstract e15075. Proceedings

III Curso AMiQ "Actualizaciones en el Cáncer de Cabeza y Cuello"

DATA14/05/2015

LLOC DE REALITZACIÓBarcelona, Spain

El papel de los anticuerpos monoclonales en el cáncer de cabeza y cuello, presente y futuro Viteri S, MD

European Lung Cancer Congress (ELCC)

DATA15/04/2015 - 18/04/2015

LLOC DE REALITZACIÓGeneva, Switzerland

Phase I/II study of brigatinib (AP26113) in patients with advanced malignancies including ALK+ NSCLC: Analysis of safety and efficiency at selected phase II doses Rosell R, Gettinger S, Bazhenova L, Langer C, Salga R, Gold K, Shaw A, Dorer D, Kerstein D, Camidge R.

International Congress on Anti-Cancer Treatment (ICACT)

DATA03/02/2015

LLOC DE REALITZACIÓParis, France

Early adaptive resistance in EGFR mutant NSCLCs and dynamic evolution of ALK positive NSCLCs Rosell R, MD, PhD

EGFR TKI early adaptive resistance. The important role of STAT3 activation Rosell R, MD, PhD

British Thoracic Oncology Group Annual Congress

DATA29/01/2015

LLOC DE REALITZACIÓDublin, Ireland

Efficacy and Safety of AP26113 in ALK+ Non–Small Cell Lung Cancer (NSCLC), Including Patients with Brain Metastases Camidge D, Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson T, Haluska FG.